Telix Pharmaceuticals Ltd.’s glioblastoma theranostic, TLX-101, is showing promising overall survival in a phase II trial in ...

By application, the US Radiotherapy market is segmented into external beam radiotherapy (EBRT) applications and internal beam radiotherapy (IBRT) applications. The external beam radiotherapy (EBRT ...

When it came to the study’s secondary endpoints of survival, Telix pointed to a median overall survival (OS) rate of 12.4 ...

Telix reports early Phase 2 data showing TLX101 improves survival in recurrent brain cancer patients, with no serious side effects observed.

Prostate cancer is the most common cancer in men worldwide. Thanks to scientific breakthroughs, there are more ways than ever to treat it — especially when it’s caught early. One ...

This is in combination with external beam radiation therapy, to patients with first or second recurrence of the disease. As well as being well tolerated with no serious adverse events, IPAX-Linz ...